Genmab A/ S Stock (DK0010272202): Quarterly earnings frame the outlook for the Nasdaq-listed biotech

Genmab A/S shares remain in focus on Nasdaq as investors digest the latest quarterly earnings, updated 2024 guidance and key antibody partnerships with US pharma majors.

Responsible: ad hoc news Earnings Desk. Reviewed prior to publication on June 16, 2026 at 8:33:49 PM ET. Details in the imprint.

Genmab A/S is back on the radar for US retail investors as the market continues to weigh the Danish biotech's most recent quarterly earnings and guidance for 2024 against a backdrop of expanding antibody partnerships and a solid cash position. Listed on Nasdaq under the ticker "GMAB", the stock has traded in a wide range over the past 12 months as expectations around key oncology franchises and pipeline assets have shifted. For investors, the latest earnings metrics and updated outlook remain the primary reference points when assessing the risk-reward profile of the Genmab equity story.

Quarterly earnings and guidance remain the key reference point

Genmab reports under IFRS and provides detailed quarterly updates on product revenue, royalties and milestone payments tied largely to its antibody collaborations, including the multiple myeloma drug Darzalex (daratumumab) marketed globally by Johnson & Johnson's Janssen unit. In its most recently reported quarter, the company highlighted continued double digit year over year growth in revenue, driven by higher royalties from Darzalex as well as increasing contribution from newer products such as Tivdak and Epkinly, which are co developed with US partners. Management reiterated that royalties from approved products are expected to remain the dominant revenue driver in 2024, with operating expenses increasing as Genmab invests in its proprietary pipeline and commercial capabilities.

According to the company's latest financial disclosure, Genmab posted total revenue in the most recent quarter of roughly DKK 3 billion, while operating income remained solidly positive despite higher research and development spending. The company guided for full year 2024 revenue in a range that implies continued growth versus 2023, albeit at a moderated pace compared with the steep ramp seen in the earlier Darzalex commercialization phase. At the same time, Genmab indicated that operating expenses will rise as it advances late stage programs in oncology and other serious diseases, which could lead to some compression in operating margin versus the prior year even if top line momentum continues.

Genmab's balance sheet remains a significant support for the investment case, with the company reporting a cash and marketable securities position in the high single digit billion DKK range at the end of the most recent quarter, and no financial debt on the balance sheet. This financial flexibility allows the company to fund internal research, support ongoing and planned clinical trials and selectively in license or co develop new antibody assets without relying on near term equity financing. The company has not announced any dividend program, and management has historically prioritized reinvesting cash flows into growth initiatives, in line with the typical strategy for development stage and early commercial biotechs.

On the income statement, royalty revenue tied to partnered products, particularly Darzalex, remains the largest single driver. Johnson & Johnson has reported that global Darzalex sales continue to grow year over year, supported by expanded indications and earlier line use in multiple myeloma, which in turn supports Genmab's royalty stream. Beyond Darzalex, Genmab's collaboration portfolio includes Teprotumumab (Tepezza) with Horizon Therapeutics and Tivdak with Pfizer, among others, although the revenue contribution from these programs is smaller and more volatile at this stage of their lifecycle. Genmab also recognizes milestone income as development, regulatory and commercial milestones are triggered under its partner agreements, which can lead to quarter to quarter fluctuations in reported revenue.

When it comes to profitability metrics, Genmab has emphasized the importance of maintaining a disciplined cost base while continuing to invest in value creating pipeline assets. Research and development expenses account for the majority of operating costs, reflecting the cost of running multiple phase 1, 2 and 3 clinical trials across a range of antibody modalities. Selling, general and administrative expenses are comparatively lower but have started to increase as Genmab builds out commercial infrastructure, including in the US, to support its co promoted products and potential future launches. The company's stated goal is to balance near term profitability with long term value creation by advancing high probability of success assets, which may lead to some variability in quarterly earnings as project timelines and clinical trial costs evolve.

From a cash flow perspective, Genmab remains free cash flow positive on a full year basis, underpinned by royalties and milestone payments that exceed operating expenditures. However, the timing of milestone receipts and the phasing of R&D spend can cause cash flow from operations to fluctuate meaningfully from quarter to quarter. As a result, investors typically assess the company's cash runway on a multi year basis, focusing on the absolute level of cash and cash equivalents and the projected burn rate under different development and commercialization scenarios.

Genmab's earnings disclosures also provide qualitative detail on the commercial performance of key products. For Darzalex, the company has pointed to continued penetration in newly diagnosed multiple myeloma, as well as in relapsed and refractory settings, with subcutaneous formulations improving patient convenience and supporting adoption. For Tivdak, an antibody drug conjugate for recurrent or metastatic cervical cancer, Genmab and its partner Pfizer are working to expand the label and improve market access, while Epkinly (epcoritamab) is being rolled out in diffuse large B cell lymphoma with an eye to additional indications in B cell malignancies. The revenue contribution from these newer assets is still emerging, but they represent important diversification of Genmab's earnings base beyond Darzalex.

Clinical development updates in the earnings materials can influence how the market values Genmab's future earnings potential. The company is advancing a range of proprietary and partnered antibodies, including bispecific T cell engaging antibodies and antibody drug conjugates, across oncology and autoimmune indications. Positive or negative trial readouts, changes in study design and regulatory interactions disclosed around the earnings date can have an outsized effect on the stock, given the sensitivity of biotech valuations to pipeline news. That sensitivity adds another layer of complexity when investors interpret quarterly earnings figures in isolation.

For US investors, the fact that Genmab reports in Danish kroner adds another variable when interpreting quarterly earnings, as reported revenue and profit in DKK must be translated into US dollars for portfolio level comparisons. Currency fluctuations between the Danish krone and the US dollar can influence the apparent growth rate when viewed from a dollar based perspective, even if underlying product volumes and local currency sales are stable. Many analysts therefore focus on constant currency growth rates and volume metrics reported by Genmab and its partners when assessing the durability of earnings trends.

Overall, the latest quarterly earnings confirm that Genmab's financial profile is still driven largely by royalties from a single blockbuster product, supplemented by early but growing contributions from newer antibodies and a sizeable cash buffer to fund future development. For now, this combination of established revenue streams, pipeline optionality and balance sheet strength continues to frame how the Nasdaq listed stock is viewed in the broader biotech space.

Genmab A/S at a glance

• Name: Genmab A/S
• Industry: Biotechnology, oncology focused antibody therapeutics
• Headquarters: Copenhagen, Denmark
• Core markets: Europe, United States, Japan and selected global markets via partners
• Revenue drivers: Royalties and milestone payments from antibody collaborations such as Darzalex, Tivdak and Epkinly, plus proprietary pipeline programs
• Listing: Nasdaq Copenhagen (GMAB) and Nasdaq Global Select Market in the US (GMAB)
• Trading currency: Danish krone on the home market and US dollars on Nasdaq

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.